Zacks Research Forecasts Lower Earnings for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) – Zacks Research lowered their Q3 2027 EPS estimates for AngioDynamics in a note issued to investors on Thursday, April 23rd. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $0.02 for the quarter, down from their prior forecast of $0.03. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.20) per share.

Several other equities research analysts also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Finally, Canaccord Genuity Group reduced their price objective on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.67.

AngioDynamics Price Performance

NASDAQ:ANGO opened at $11.20 on Friday. AngioDynamics has a 1-year low of $8.36 and a 1-year high of $13.99. The firm has a 50-day moving average of $10.82 and a two-hundred day moving average of $11.49. The stock has a market cap of $462.78 million, a P/E ratio of -14.93 and a beta of 0.43.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The company had revenue of $78.42 million for the quarter, compared to analyst estimates of $76.77 million. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ANGO. State of Alaska Department of Revenue acquired a new stake in AngioDynamics in the third quarter worth $25,000. Farther Finance Advisors LLC grew its position in shares of AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares during the last quarter. Washington Trust Advisors Inc. bought a new position in shares of AngioDynamics during the third quarter worth about $27,000. Kemnay Advisory Services Inc. acquired a new stake in shares of AngioDynamics in the 4th quarter worth about $27,000. Finally, State of Wyoming bought a new stake in AngioDynamics in the 2nd quarter valued at about $31,000. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.